PDS Biotechnology (PDSB) stock price is up over 61% this past year. PDS Biotechnology director, president, and CEO, Dr. Frank Bedu, weighs in on the latest trial results that indicated 100% clinical response for treatment of cervical cancer patients with large tumors using a combination of PDS101 with standard-of-care chemoradiotherapy. All patients had a tumor shrinkage of 60% or greater.
22 Jan 2023
Trading 360
04 May 2023
The Watch List
17 May 2023
Market On Close
03 May 2023
Market On Close
28 Mar 2023
Market On Close
23 May 2023
Next Gen Investing
18 Apr 2023